Pharma Focus Asia

Eli Lilly Invests US$9 billion to Expand Manufacturing Site in Indiana, USA


Eli Lilly invests US$9 million in the newest Indiana site to boost API production for tirzepatide and pipeline medicines in USA.


This expansion will increase the capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection, allowing more adults with chronic conditions such as obesity and type 2 diabetes to benefit from these vital treatments.

The multi-site campus will produce cutting-edge medications, including Zepbound and Mounjaro, support pipeline growth, and utilise the latest technology and automation for optimal efficiency, safety, and quality control.

Significantly, this investment creates high-wage, advanced manufacturing, engineering, and science jobs.

As part of this additional investment, the Lebanon site expects to add 200 full-time jobs for highly skilled workers, including engineers, scientists, operating personnel, and lab technicians, resulting in an estimated 900 full-time employees when the facility is fully operational.

The site is anticipated to start manufacturing medicines in Lebanon toward the end of 2026, with operations scaling up through 2028.


Name    Eli Lilly
Type       New Construction
Budget  US$9 billion
Year        2028


magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference